XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
Series A & B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Non-Controlling Interest [Member]
Total
Balance at beginning at Dec. 31, 2019 $ 132 $ 3,318 $ 101,099,347 $ (88,650,465) $ (5,511,624) $ 8,242 $ 6,948,950
Balance at beginning (in shares) at Dec. 31, 2019 132,040 3,318,390          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock based compensation: Options 19,956 19,956
Stock based compensation: Common stock $ 65 73,385 73,450
Stock based compensation: Common Stock (Shares) 65,000          
Issuance of common stock in payment of short term advances, related party $ 661 739,287 739,948
Issuance of common stock in payment of short term advances, related party (in shares) 660,667          
Issuance of common stock in payment of accrued liabilities $ 13 73,141 73,154
Issuance of common stock in payment of accrued liabilities (in shares) 12,500          
Issuance of common stock for conversion of debt $ 1,345 2,118,617 2,119,962
Issuance of common stock for conversion of debt (in shares) 1,345,164          
Beneficial conversion feature in connection with convertible notes 20,345 20,345
Fair value warrants issued in connection with convertible notes 414,895 414,895
Comprehensive loss:              
Net income\loss (6,531,548) (6,531,548)
Preferred dividends (4,460) (4,460)
Net unrealized loss on derivatives in related party (1,242,094) (1,242,094)
Foreign currency translation adjustments (148,607) (148,607)
Balance at ending at Mar. 31, 2020 $ 132 $ 5,402 104,558,973 (95,186,473) (6,902,325) 8,242 2,483,951
Balance at ending (in shares) at Mar. 31, 2020 132,040 5,401,721          
Balance at beginning at Dec. 31, 2020 $ 132 $ 27,754 171,397,199 (121,396,715) (1,717,934) 821,647 49,132,083
Balance at beginning (in shares) at Dec. 31, 2020 132,040 27,753,562          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock based compensation: Options 19,602 19,602
Issuance of common stock for cash $ 21,562 124,961,743 124,983,305
Issuance of common stock for cash (in shares) 21,561,900          
Issuance of common stock for conversion of convertible notes payable $ 183 449,333 449,516
Issuance of common stock for conversion of convertible notes payable (in shares) 183,214          
Financing cost in connection with sales of common stock (4,064,837) (4,064,837)
Comprehensive loss:              
Net income\loss 1,997,381 1,997,381
Preferred dividends (4,400) (4,400)
Net unrealized loss on derivatives in related party 2,969,170 2,969,170
Foreign currency translation adjustments (92,694) (92,694)
Net loss attributable to non-controlling interest           1,080,586 1,080,586
Balance at ending at Mar. 31, 2021 $ 132 $ 49,499 $ 292,763,040 $ (119,403,734) $ 1,158,542 $ 1,902,233 $ 176,469,712
Balance at ending (in shares) at Mar. 31, 2021 132,040 49,498,676